Martinus Capelle | Distinguished Scientist II
Janssen

Innovative Drug Product and CMC leader with ~25 years of experience across pre‑clinical to late‑stage development and launch. Expertise spans formulation, biopharmaceutics, advanced analytical development, fill/finish, and manufacturing of biologics, including peptides, proteins, multi-specific mAbs, vaccines, viral, cell-gene therapies and RNA‑LNPs. Holds a PhD in Pharmaceutical Technology (University of Geneva); previously collaborated with multiple biotech/pharma companies at Therapeomic (CRO, Basel) and has held roles of increasing responsibility at J&J since 2012. Furthernore, he founded his consulting firm Calyvic in 2026.